期刊
AMERICAN JOURNAL OF PATHOLOGY
卷 178, 期 1, 页码 12-18出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2010.08.004
关键词
-
类别
资金
- Research Concerted Action program
- CEE [HEALTH-F2-2007-201342]
- National Fund for Scientific Research (NFSR, Belgium)
- TELEVIE
- Centre Anti-Cancereux of the University of Liege
- GIGA-Proteomics Platform at the University of Liege, Belgium
The discovery of biomarkers that are readily accessible through the circulating blood and are selectively over-expressed in pathological tissues has become a major research objective, particularly in the field of oncology. Indisputably, this group of molecules has a high potential to serve as an innovative tool for effective imaging and targeted cancer therapy approaches. In this attractive therapeutic concept, specific cancer proteins are reached by intravenously administered ligands that are coupled to cytotoxic drugs. Such compounds are able to induce cancer destruction while sparing normal tissues. Owing to the performance of mass spectrometry technology, current high-throughput proteomic analysis allows for the identification of a high number of proteins that are differentially expressed in the cancerous tissues. However, such approaches provide no information regarding the effective accessibility of the >biomarkers and, therefore, the possibility for these discovered proteins to be targeted. To bypass this major limitation, which clearly slows the discovery of such biomarkers, innovative methodological strategies have been developed to enrich the clinical specimens before the mass spectrometry analysis. The focus is laid on the group of proteins that are necessarily located either at the exterior face of the plasma membrane or in the extracellular matrix. The present review addresses the current technologies meant for the discovery and analysis of accessible antigens from clinically relevant samples. (Am J Pathol 2011, 178:12-18. DOI: 10.1016/j.ajpath.2010.08.004)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据